RT Journal Article
T1 Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection.
A1 Monforte, Victor
A1 Sintes, Helena
A1 Ussetti, Piedad
A1 Castejon, Raquel
A1 Pérez, Virginia Luz
A1 Laporta, Rosalia
A1 Sole, Amparo
A1 Cifrian, Jose Manuel
A1 Marcos, Pedro J
A1 Redel, Javier
A1 Los-Arcos, Ibai
A1 Saez, Berta
A1 Alonso, Rodrigo
A1 Rosado, Silvia
A1 Escriva, Juan
A1 Iturbe, David
A1 Ovalle, Juan Pablo
A1 Vaquero, Jose Manuel
A1 Revilla, Eva
A1 Mendoza, Alberto
A1 Gomez-Olles, Susana
K1 Transplant Recipients
K1 Spain
K1 Cytomegalovirus Infections
K1 Organ Transplantation
K1 Immunosuppression Therapy
AB Lung transplant recipients (LTR) are at significantly higher risk for cytomegalovirus (CMV) infection compared to recipients of other solid organ transplants (SOT), with both the direct and indirect effects of CMV infection contributing to increased morbidity and mortality in this population. Current guidelines recommend universal antiviral prophylaxis for a duration of 6 to 12 months depending on the recipient’s CMV serostatus. However, prolonged antiviral use is associated with adverse effects, often necessitating early discontinuation of prophylaxis. To address this, several authors have proposed the use of the Quantiferon®-CMV assay as a tool to stratify the risk of CMV disease in SOT recipients, which could facilitate more personalized prophylaxis strategies. Nevertheless, its utility in CMV-seropositive lung transplant recipients (LTR+), who represent 80–90% of LTRs in Spain, remains unclear. Notably, it has been reported that up to 20% of LTR+ patients with high Quantiferon®-CMV responses still develop CMV infection. A potential explanation for this paradox is that high levels of immunosuppression may suppress other critical immune pathways involved in CMV control. The overall intensity of immunosuppression can be evaluated using the Immuknow® assay. Based on this, we hypothesized that the risk of CMV infection in LTR+ patients could be more accurately stratified by combining results from both the Quantiferon®-CMV and Immuknow® assays.
PB Elsevier
YR 2021
FD 2021
LK http://hdl.handle.net/10668/22001
UL http://hdl.handle.net/10668/22001
LA en
LA es
NO Monforte V, Sintes H, Ussetti P, Castejón R, Pérez VL, Laporta R, et al. Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection. Arch Bronconeumol. 2022 Aug;58(8):614-617. English, Spanish
DS RISalud
RD Oct 11, 2025